QLT Inc. (QLT), is a global biopharmaceutical company engaged in the business of discovering, developing and commercialization of therapies. QLT has two commercial products, Visudyne and Eligard. Visudyne utilizes photodynamic therapy (PDT), to treat the eye disease known as wet age related macular degeneration (wet AMD), the cause of blindness in people over the age of 55 in North America and Europe. Visudyne is also used for the treatment of subfoveal choroidal neovascularization (CNV) due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The Eligard product line includes one, three, four and six month commercial formulations of Atrigel technology combined with leuprolide acetate. In October 2009, the Company completed the sale of its entire interest in its wholly owned subsidiary, QLT USA, Inc. to TOLMAR Holding, Inc.